Future Science Group
infographic.pdf (325.41 kB)

Real-world effectiveness of sofosbuvir/velpatasvir for the treatment of hepatitis C virus in prison settings: infographic

Download (325.41 kB)
posted on 2022-05-03, 09:42 authored by Silvia Rosati, Alexander Wong, Vito Di Marco, Paco Pérez-Hernandez, Guilherme Macedo, Christian Brixko, Roberto Ranieri, Francesca Campanale, Annalisa Basciá, Conrado Fernández-Rodríguez, Victor de Lédinghen, Ivana Maida, Elisabetta Teti, Alessandra Mangia, Kim Vanstraelen, Cándido Hernández, Michael Mertens, Ioanna Ntalla, Heribert Ramroth, Elena Jiménez

 Background: People in prison are at high risk of hepatitis C virus (HCV) infection and often have a history of injection drug use and mental health disorders. Simple test-and-treat regimens which require minimal monitoring are critical. Methods: This integrated real-world analysis evaluated the effectiveness of once daily sofosbuvir/velpatasvir (SOF/VEL) in 20 prison cohorts across Europe and Canada. The primary outcome was sustained virological response (SVR) in the effectiveness population (EP), defined as patients with a valid SVR status. Secondary outcomes were reasons for not achieving SVR, adherence and time between HCV RNA diagnosis and SOF/VEL treatment. Results: Overall, 526 people in prison were included with 98.9% SVR achieved in the EP (n = 442). Cure rates were not compromised by drug use or existence of mental health disorders. Conclusion: SOF/VEL for 12 weeks is highly successful in prison settings and enables the implementation of a simple treatment algorithm in line with guideline recommendations and test-and-treat strategies. 


Usage metrics

    Future Virology


    Ref. manager